Short Communication

Suppression of Hepatic CYP3A4 Expression and Activity by 3-Methylcholanthrene in Humanized PXR-CAR-CYP3A4/3A7 Mice[□]

Received September 13, 2018; accepted December 19, 2018

ABSTRACT

Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants that activate the aryl hydrocarbon receptor, thereby triggering a range of biologic responses, exemplified by the induction of *CYP1A1*. PAHs can also regulate the expression of members of the *CYP3A* subfamily, with reports of mainly suppressive effects on mouse hepatic *Cyp3a11* expression, but paradoxically both inductive and suppressive effects on human hepatic *CYP3A4* expression. Understanding the regulation of *CYP3A4* expression by PAHs is important because of the widespread exposure of humans to these chemicals and the central role of the *CYP3A4* enzyme in the metabolism of clinically important drugs and endogenous substances. The present study used 3-methylcholanthrene (MC) as a model PAH to characterize the in vivo regulation of *CYP3A4* expression and activity in humanized

pregnane X receptor–constitutive androstane receptor–*CYP3A4/3A7* mice. Adult mice were treated by intraperitoneal injection with MC (80 mg/kg), or corn oil vehicle, and euthanized 24 or 72 hours later. As a positive control response, pronounced induction of hepatic *Cyp1a1* by MC was confirmed at both time points in males and females at the mRNA, protein, and catalytic activity levels. Basal hepatic *CYP3A4* expression and activity were significantly higher in female versus male mice. MC treatment suppressed hepatic *CYP3A4* in female mice at 72 hours postdosing at the mRNA, protein, and catalytic activity levels. A similar response was observed in male mice, although the suppression of *CYP3A4* protein levels did not achieve statistical significance. This mouse model will facilitate further studies of the mechanisms and consequences of *CYP3A4* suppression by PAHs.

Introduction

CYP3A4 is among the most important human drug-metabolizing enzymes, due to its abundant hepatic and gastrointestinal expression, broad substrate selectivity, and susceptibility to induction and inhibition (Guengerich, 1999). Although polycyclic aromatic hydrocarbons (PAHs), important carcinogenic constituents of cigarette smoke and other combustion sources, are known to induce multiple cytochrome P450s (P450s) such as *CYP1A1*, *CYP1A2*, and *CYP1B1* via activation of the aryl hydrocarbon receptor (AHR) (Nebert et al., 2004), the regulation of human *CYP3A4* by these chemicals is poorly characterized.

Studies of the regulation of the major *CYP3A4* counterpart in mice (*Cyp3a11*) by 3-methylcholanthrene (MC), a model PAH that is readily biotransformed by P450s (Riddick et al., 1994), have provided valuable insight. Our laboratory showed a pronounced loss of mouse hepatic *Cyp3a11* protein triggered by MC treatment (Lee et al., 2006) and subsequently established that the suppression of *Cyp3a11* mRNA and protein caused by MC is comparable in wild-type and liver *Cpr*-null mice that are nearly devoid of hepatic microsomal P450 activity due to hepatocyte-specific conditional deletion of NADPH-cytochrome P450 oxidoreductase (Lee et al., 2013a). Thus, MC appears to down-regulate mouse hepatic *Cyp3a11* via a pretranslational mechanism that does not require hepatic microsomal P450-dependent activity. Using 2,3,7,8-tetrachlorodibenzo-*p*-dioxin as an essentially nonmetabolized

AHR agonist and *Ahr*-null mice, our laboratory demonstrated the AHR dependence of the suppression of hepatic *Cyp3a11* mRNA levels (Lee and Riddick, 2012).

Smokers show decreased *CYP3A4*-mediated metabolism of some (Jokinen et al., 2001), but not all, substrates (He et al., 2006). MC treatment suppresses *CYP3A4* expression and activity in cultured primary human hepatocytes (Richert et al., 2009). Paradoxically, MC exposure increases *CYP3A4* mRNA levels in the HepG2 human hepatocellular carcinoma cell line (Westerink and Schoonen, 2007). This induction response was reported to require activation of the human, but not mouse, pregnane X receptor (PXR) (Kumagai et al., 2012), a nuclear receptor with a central role in the transcriptional regulation of *CYP3A4* expression. Further in vitro studies showed that PAHs and their phase I metabolites can activate human PXR (Luckert et al., 2013). More recently, evidence has emerged for bidirectional inhibitory crosstalk between AHR and PXR. First, activated PXR can bind directly to AHR and inhibit AHR binding to, and activation of, specific target genes (Cui et al., 2017). Second, studies in primary human hepatocytes and HepaRG cells showed that AHR activation decreases *CYP3A4* expression and inducibility by PXR activators (Rasmussen et al., 2017).

To overcome limitations associated with wild-type mice and human continuous cell lines in studies of human *CYP3A4* regulation and to attempt to resolve confusion regarding the effects of PAHs on this key enzyme, we studied the regulation of *CYP3A4* expression and activity by MC in an in vivo context with an intact endocrine system using humanized PXR–constitutive androstane receptor (CAR)–*CYP3A4/3A7* mice (Hasegawa et al., 2011). In this targeted replacement model, the mouse genes encoding the PXR and CAR are replaced with the human orthologous genes, and seven full-length mouse *Cyp3a* genes located in

This work was supported by the Canadian Institutes of Health Research [Grant MOP-142442].

<https://doi.org/10.1124/dmd.118.084509>.

[□]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: AHR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; GH, growth hormone; MC, 3-methylcholanthrene; P450, cytochrome P450; PAH, polycyclic aromatic hydrocarbon; PXR, pregnane X receptor.

a cluster on chromosome 5 (*Cyp3a11*, 16, 25, 41, 44, 57, and 59) are replaced with 125 kb of human genomic DNA comprising *CYP3A4*, *CYP3A7*, and their regulatory regions.

Materials and Methods

Treatment of Humanized PXR-CAR-CYP3A4/3A7 Mice. The University of Toronto Animal Care Committee approved all animal protocols and experiments, following the principles established by the Canadian Council on Animal Care (<https://www.cac.ca/en/standards/>). Male and female humanized PXR-CAR-CYP3A4/3A7 mice (model 11585) were purchased from Taconic Biosciences (Hudson, NY), with arrival at the Division of Comparative Medicine, University of Toronto at 4–7 weeks of age. After a period of acclimatization to housing conditions with same-sex littermates (12-hour light-dark cycle with lights on from 7:00 AM to 7:00 PM, ad libitum access to water and food) experimentation commenced when mice were 8–9 weeks of age. Mice received a single intraperitoneal injection of MC (80 mg/kg), or corn oil vehicle, followed by euthanasia by cervical dislocation at 24 or 72 hours after dosing. Livers were processed for total RNA isolation and microsome preparation as described previously (Lee et al., 2006), with microsome protein determination by the method of Lowry et al. (1951).

Analysis of mRNA Levels by Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction. Hepatic mRNA levels for all target genes, normalized to mouse β -actin as the internal reference standard, were determined in triplicate using the comparative threshold cycle method described previously (Lee and Riddick, 2012). Primer sequences were derived from published sources as follows: mouse *Cyp1a1* (Xu and Miller, 2004), human *CYP3A4* (Miyoshi et al., 2002), and mouse fibroblast growth factor 21 (*Fgf21*) (Woolsey et al., 2016).

Immunoblot Analysis. Nitrocellulose membranes containing resolved hepatic microsomal proteins were probed with the following primary antibodies: mouse monoclonal against rat *Cyp1a1* (MAb 1-31-2; Dr. Harry Gelboin, National Cancer Institute, Bethesda, MD) (Park et al., 1982) used at a 1:5000 dilution, and mouse monoclonal against human *CYP3A4* (MAb 275-1-2; Kristopher Krausz, National Cancer Institute, Bethesda, MD) (Gelboin et al., 1995) used at dilutions of 1:500 (male samples) or 1:1000 (female samples). For relative quantitation of *CYP3A4* protein levels, films derived from enhanced chemiluminescence detection were scanned and subjected to densitometric analysis using ImageJ software (National Institutes of Health, Bethesda, MD), with normalization to total protein as a loading control as determined using Revert Total Protein Stain (Li-Cor Biosciences, Lincoln, NE). *Cyp1a1* immunoblots were assessed visually as a qualitative positive control response.

Catalytic Activity Assays. Using our previously reported methods (Lee et al., 2013a,b), modified such that each reaction contained 1 μ g of hepatic microsomal protein, P450-Glo assays (Promega, Madison, WI) were used to assess mouse *Cyp1a1* activity, with luciferin 6'-chloroethyl ether as substrate, and human *CYP3A4* activity, with luciferin isopropyl acetal as substrate (Cali et al., 2012).

Statistical Analysis. The sample size of five mice per treatment group provides 80% power ($\beta = 0.20$) at a significance level of $\alpha = 0.05$, to detect cases

where the ratio of the estimated S.D. to the minimum effect magnitude is 0.56 (e.g., a 45% increase or decrease in a measured outcome with a S.D. for that parameter equal to 25% of the mean). For *CYP3A4* protein levels, where the marked difference in basal expression between sexes (female > male) necessitated the use of different experimental conditions for each sex, data were analyzed initially using randomized-design two-way analysis of variance to identify the effects of the two independent variables and their interaction (MC treatment; time; treatment $\times$ time interaction). All other data were analyzed initially using randomized-design three-way analysis of variance to identify the effects of the three independent variables and their interactions (MC treatment; time; sex; all pairwise two-factor interactions and three-factor interaction). Bonferroni-corrected post tests were performed for the planned comparisons to discern specific MC treatment, time, and sex effects. If Bartlett's test showed significant heterogeneity of variance, specific comparisons of interest were based on the nonparametric Mann-Whitney test.

Results and Discussion

Male and female humanized PXR-CAR-CYP3A4/3A7 mice were exposed to MC under conditions previously shown to downregulate hepatic *Cyp3a11* expression and activity in male wild-type C57BL/6 mice (Lee et al., 2006, 2013a). MC treatment had minimal effects on the liver to body weight ratio, with a 25% increase seen at 72 hours postdosing only in females (Supplemental Fig. 1). As a positive control for AHR activation, MC caused pronounced induction of hepatic *Cyp1a1* at both time points in females and males at the mRNA, protein, and catalytic activity levels (Fig. 1).

Basal hepatic *CYP3A4* expression was higher in female versus male mice at the mRNA, protein, and catalytic activity levels (Fig. 2); the sex difference in *CYP3A4* protein levels was so pronounced that male and female samples could not be analyzed under the same conditions. The original publication describing the humanized PXR-CAR-CYP3A4/3A7 mouse model (Hasegawa et al., 2011) did not report a sex difference in hepatic *CYP3A4* expression; however, other *CYP3A4*-transgenic mouse models have consistently found higher *CYP3A4* expression in the liver of adult females versus males (Yu et al., 2005; Cheung et al., 2006; Kobayashi et al., 2017). This parallels the higher expression and activity of *CYP3A4* seen in female human liver (Wolbold et al., 2003) and is attributed to the stimulatory influence of the continuous growth hormone (GH) secretion pattern characteristic of females (Cheung et al., 2006). Several transcription factors are implicated in the female-predominant expression of *CYP3A4* driven by a continuous GH profile: signal transducer and activator of transcription-5 (Lamba et al., 2016); PXR and hepatocyte nuclear factor-4 α (Thangavel et al., 2011); hepatocyte nuclear factor-6, CCAAT-enhancer binding protein- α , and retinoid X receptor- α (Li et al., 2015).

Fig. 1. Effects of MC treatment, time, and sex on hepatic *Cyp1a1* mRNA levels (A), *Cyp1a1* protein levels (B), and luciferin 6'-chloroethyl ether (Luc-CEE) activity (C). (B) Immunoblot of microsomal protein (5 μ g) using MAb 1-31-2 against rat *Cyp1a1*, showing results for two vehicle-treated (V) or MC-treated mice per time point. (A and C) Data represent the mean $\pm$ S.D. of determinations from four (male 24-hour vehicle group) or five (all others) mice per group, expressed as a percentage of the mean for the female 24-hour vehicle group. Data were analyzed initially by three-way analysis of variance (ANOVA), and the *P* values for the ANOVA main effects are shown in Supplemental Table 1. Outcomes from Bonferroni-corrected post tests were as follows: * denotes significantly different ($P < 0.05$) from sex- and time-matched vehicle control; † denotes significantly different ($P < 0.05$) from sex- and treatment-matched 24-hour group; and ‡ denotes significantly different ($P < 0.05$) from time- and treatment-matched female group. The 24- and 72-hour designations indicate the time postdosing with vehicle or MC.

Fig. 2. Effects of MC treatment, time, and sex on hepatic CYP3A4 mRNA levels (A), CYP3A4 protein levels (B), and luciferin isopropyl acetal (Luc-IPA) activity (C). (B) Immunoblot of microsomal protein (5 μ g for female and 25 μ g for male) using MAb 275-1-2 against human CYP3A4, showing results for two vehicle-treated (V) or MC-treated mice per time point. (A–C) Data represent the mean $\pm$ S.D. of determinations from four (male 24-hour vehicle group) or five (all others) mice per group, expressed as a percentage of the mean for the female 24-hour vehicle group (A and C) or the sex-matched 24-hour vehicle group (B). Data were analyzed initially by three-way analysis of variance (ANOVA) (A and C) or two-way ANOVA (B), and the *P* values for the ANOVA main effects are shown in Supplemental Table 1 (A and C) and Supplemental Table 2 (B). Outcomes from Bonferroni-corrected post tests or nonparametric Mann-Whitney tests were as follows: * denotes significantly different (*P* < 0.05) from sex- and time-matched vehicle control; † denotes significantly different (*P* < 0.05) from sex- and treatment-matched 24-hour group; and ‡ denotes significantly different (*P* < 0.05) from time- and treatment-matched female group. The 24- and 72-hour designations indicate the time postdosing with vehicle or MC.

MC treatment suppressed hepatic CYP3A4 in female and male mice at 72 hours postdosing at the mRNA (Fig. 2A) and catalytic activity (Fig. 2C) levels. The downregulation of CYP3A4 protein levels by MC (Fig. 2B) achieved statistical significance in females but not males, likely because of the very low and variable levels of CYP3A4 protein seen in the liver of male mice. At the protein level, similar results were obtained using an independent primary rabbit polyclonal raised against a peptide specific for human CYP3A4 (product no. 458234; Corning-Gentest, Woburn, MA) at 1:1000 dilution (data not shown). The influence of sex on the developmental profile of hepatic CYP3A4 expression in humanized PXR-CAR-CYP3A4/3A7 mice has not been reported. In other CYP3A4-transgenic mouse models (Yu et al., 2005; Cheung et al., 2006) prepubertal males and females display similar hepatic CYP3A4 expression. It would be interesting to study the regulation of hepatic CYP3A4 expression by PAHs in humanized PXR-CAR-CYP3A4/3A7 mice at earlier prepubertal developmental stages, keeping in mind that the sexually dimorphic pituitary GH secretion profiles are not yet established (Gabriel et al., 1992) and hepatic factors needed to impart GH-controlled sex differences in liver gene expression patterns are absent in prepubertal rodents (Choi and Waxman, 2000).

To explore potential mechanistic links between AHR activation and CYP3A4 suppression, we measured hepatic mRNA levels for the metabolic hormone FGF21. Depending on dose, AHR agonists can either induce (Cheng et al., 2014; Lu et al., 2015) or suppress (Girer et al., 2016) mouse hepatic Fgf21 expression. Elevated hepatic FGF21 levels can

trigger phosphorylation-dependent trapping of PXR in the cytoplasm, leading to decreased PXR-stimulated CYP3A4 transcription (Woolsey et al., 2016). We found that MC treatment induced hepatic Fgf21 mRNA levels at 72 hours postdosing, but only in male mice (Fig. 3). Although interesting, this result does not support a role for Fgf21 in the suppression

Fig. 3. Effects of MC treatment, time, and sex on hepatic Fgf21 mRNA levels. Data represent the mean $\pm$ S.D. of determinations from four (male 24-hour vehicle group) or five (all others) mice per group, expressed as a percentage of the mean for the female 24-hour vehicle group. Data were analyzed initially by three-way analysis of variance (ANOVA), and the *P* values for the ANOVA main effects are shown in Supplemental Table 1. Outcomes from Bonferroni-corrected post tests were as follows: * denotes significantly different (*P* < 0.05) from sex- and time-matched vehicle control; and ‡ denotes significantly different (*P* < 0.05) from time- and treatment-matched female group. The 24- and 72-hour designations indicate the time postdosing with vehicle or MC.

of *CYP3A4* expression by MC, which was observed in both sexes. Levels of two FGF21 target transcripts (c-Fos and early growth response protein 1) were not impacted by MC treatment (data not shown). We also explored other pathways commonly implicated in P450 downregulation responses and MC was found to have no significant effect on the following marker transcripts: endoplasmic reticulum stress (78-kDa glucose-regulated protein; activating transcription factor-4; X-box binding protein-1 spliced); inflammation mediators (interleukin-6 and tumor necrosis factor- α) and markers (suppressor of cytokine signaling-3 and serum amyloid protein P); and peroxisome proliferator-activated receptor- α target (pyruvate dehydrogenase kinase-4) (data not shown).

This study shows that PAH exposure in an in vivo context results in suppression of hepatic *CYP3A4* expression and activity. Importantly, this contrasts with a PXR-mediated induction response seen in human continuous cell lines (e.g., HepG2), likely related to altered basal and inducible expression of P450s, transcription factors, and coregulators in cell lines. The humanized PXR-CAR-*CYP3A4/3A7* mouse model will facilitate further studies of the mechanisms and consequences of *CYP3A4* suppression by PAHs.

Acknowledgments

We thank Chunja Lee for technical assistance as well as Kristopher Krausz and the late Dr. Harry Gelboin (National Cancer Institute, Bethesda, MD) for providing antibodies.

Department of Pharmacology and
Toxicology, University of Toronto,
Toronto, Ontario, Canada

MICHAEL CROSBY
DAVID S. RIDDICK

Authorship Contributions

Participated in research design: Crosby, Riddick.

Conducted experiments: Crosby, Riddick.

Performed data analysis: Crosby, Riddick.

Wrote or contributed to the writing of the manuscript: Crosby, Riddick.

References

- Cali JJ, Ma D, Wood MG, Meisenheimer PL, and Klaubert DH (2012) Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates. *Expert Opin Drug Metab Toxicol* **8**:1115–1130.
- Cheng X, Vispute SG, Liu J, Cheng C, Kharitonov A, and Klaassen CD (2014) Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR). *Toxicol Appl Pharmacol* **278**:65–71.
- Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, and Gonzalez FJ (2006) Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. *J Pharmacol Exp Ther* **316**:1328–1334.
- Choi HK and Waxman DJ (2000) Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. *Endocrinology* **141**:3245–3255.
- Cui H, Gu X, Chen J, Xie Y, Ke S, Wu J, Golovko A, Morpurgo B, Yan C, Phillips TD, et al. (2017) Pregnane X receptor regulates the AhR/Cyp1A1 pathway and protects liver cells from benzo[α]-pyrene-induced DNA damage. *Toxicol Lett* **275**:67–76.
- Gabriel SM, Roncancio JR, and Ruiz NS (1992) Growth hormone pulsatility and the endocrine milieu during sexual maturation in male and female rats. *Neuroendocrinology* **56**:619–628.
- Gelboin HV, Krausz KW, Goldfarb I, Buters JTM, Yang SK, Gonzalez FJ, Korzekwa KR, and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. *Biochem Pharmacol* **50**:1841–1850.
- Girer NG, Murray IA, Omiecinski CJ, and Perdew GH (2016) Hepatic aryl hydrocarbon receptor attenuates fibroblast growth factor 21 expression. *J Biol Chem* **291**:15378–15387.
- Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* **39**:1–17.
- Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, and Scheer N (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. *Mol Pharmacol* **80**:518–528.
- He P, Court MH, Greenblatt DJ, and von Moltke LL (2006) Factors influencing midazolam hydroxylation activity in human liver microsomes. *Drug Metab Dispos* **34**:1198–1207.
- Jokinen MJ, Olkkola KT, Ahonen J, and Neuvonen PJ (2001) Effect of rifampin and tobacco smoking on the pharmacokinetics of ropiacaine. *Clin Pharmacol Ther* **70**:344–350.
- Kobayashi K, Abe C, Endo M, Kazuki Y, Oshimura M, and Chiba K (2017) Gender difference of hepatic and intestinal *CYP3A4* in *CYP3A* humanized mice generated by a human chromosome-engineering technique. *Drug Metab Lett* **11**:60–67.
- Kumagai T, Suzuki H, Sasaki T, Sakaguchi S, Miyairi S, Yamazoe Y, and Nagata K (2012) Polycyclic aromatic hydrocarbons activate *CYP3A4* gene transcription through human pregnane X receptor. *Drug Metab Pharmacokin* **27**:200–206.
- Lamba V, Jia B, and Liang F (2016) STAT5A and STAT5B have opposite correlations with drug response gene expression. *Biochem Biophys Res Commun* **479**:117–124.
- Lee C, Ding X, and Riddick DS (2013a) Downregulation of mouse hepatic *CYP3A* protein by 3-methylcholanthrene does not require cytochrome P450-dependent metabolism. *Drug Metab Dispos* **41**:1782–1786.
- Lee C, Ding X, and Riddick DS (2013b) The role of cytochrome P450-dependent metabolism in the regulation of mouse hepatic growth hormone signaling components and target genes by 3-methylcholanthrene. *Drug Metab Dispos* **41**:457–465.
- Lee C, Hutson JR, Tzau VKF, and Riddick DS (2006) Regulation of constitutive mouse hepatic cytochromes P450 and growth hormone signaling components by 3-methylcholanthrene. *Drug Metab Dispos* **34**:1530–1538.
- Lee C and Riddick DS (2012) Aryl hydrocarbon receptor-dependence of dioxin's effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components. *Can J Physiol Pharmacol* **90**:1354–1363.
- Li J, Wan Y, Na S, Liu X, Dong G, Yang Z, Yang J, and Yue J (2015) Sex-dependent regulation of hepatic *CYP3A* by growth hormone: roles of HNF6, C/EBP α , and RXR α . *Biochem Pharmacol* **93**:92–103.
- Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**:265–275.
- Lu P, Yan J, Liu K, Garbacz WG, Wang P, Xu M, Ma X, and Xie W (2015) Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21. *Hepatology* **61**:1908–1919.
- Luckert C, Ehlers A, Buhke T, Seidel A, Lampen A, and Hessel S (2013) Polycyclic aromatic hydrocarbons stimulate human *CYP3A4* promoter activity via PXR. *Toxicol Lett* **222**:180–188.
- Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, and Noguchi S (2002) Prediction of response to docetaxel by *CYP3A4* mRNA expression in breast cancer tissues. *Int J Cancer* **97**:129–132.
- Nebert DW, Dalton TP, Okey AB, and Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. *J Biol Chem* **279**:23847–23850.
- Park SS, Fujino T, West D, Guengerich FP, and Gelboin HV (1982) Monoclonal antibodies that inhibit enzyme activity of 3-methylcholanthrene-induced cytochrome P-450. *Cancer Res* **42**:1798–1808.
- Rasmussen MK, Daujat-Chavanieu M, and Gerbal-Chaloin S (2017) Activation of the aryl hydrocarbon receptor decreases rifampicin-induced *CYP3A4* expression in primary human hepatocytes and HepaRG. *Toxicol Lett* **277**:1–8.
- Richert L, Tuschl G, Abadie C, Blanchard N, Pekthong D, Manton G, Weber JC, and Mueller SO (2009) Use of mRNA expression to detect the induction of drug metabolizing enzymes in rat and human hepatocytes. *Toxicol Appl Pharmacol* **235**:86–96.
- Riddick DS, Huang Y, Harper PA, and Okey AB (1994) 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin versus 3-methylcholanthrene: comparative studies of Ah receptor binding, transformation, and induction of CYP1A1. *J Biol Chem* **269**:12118–12128.
- Thangavel C, Boopathi E, and Shapiro BH (2011) Intrinsic sexually dimorphic expression of the principal human *CYP3A4* correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men. *Endocrinology* **152**:4813–4824.
- Westerink WM and Schoonen WG (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. *Toxicol In Vitro* **21**:1581–1591.
- Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of *CYP3A4* expression in human liver. *Hepatology* **38**:978–988.
- Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, Adams PC, Kim RB, and Tirona RG (2016) A fibroblast growth factor 21-pregnane X receptor pathway down-regulates hepatic *CYP3A4* in nonalcoholic fatty liver disease. *Mol Pharmacol* **90**:437–446.
- Xu M and Miller MS (2004) Determination of murine fetal *Cyp1a1* and *1b1* expression by real-time fluorescence reverse transcription-polymerase chain reaction. *Toxicol Appl Pharmacol* **201**:295–302.
- Yu AM, Fukamachi K, Krausz KW, Cheung C, and Gonzalez FJ (2005) Potential role for human cytochrome P450 3A4 in estradiol homeostasis. *Endocrinology* **146**:2911–2919.

Address correspondence to: Dr. David S. Riddick, Department of Pharmacology and Toxicology, Medical Sciences Building, University of Toronto, Toronto, ON, Canada M5S 1A8. E-mail: david.riddick@utoronto.ca